<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159418</url>
  </required_header>
  <id_info>
    <org_study_id>SKSD00702</org_study_id>
    <nct_id>NCT01159418</nct_id>
  </id_info>
  <brief_title>LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors</brief_title>
  <official_title>A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Europe New Drug Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Europe New Drug Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of Panobinostat&#xD;
      (LBH589) when administered in combination with Carboplatin and Paclitaxel in patients with&#xD;
      advanced solid malignancies and to identify the Recommended Dose (RD) for a subsequent Phase&#xD;
      II study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of Carboplatin (C) and Paclitaxel (PTX) is considered standard treatment in&#xD;
      patients with epithelial ovarian cancer and endometrial cancer, in USA and in those in whom&#xD;
      anthracyclines are not recommended. In cervical cancer, where very often the renal function&#xD;
      is impaired, C represents a convenient substitute of cisplatin in the combination with PTX;&#xD;
      in NSCLC the C and PTX regimen is first choice therapy for outpatient treatment first or&#xD;
      second line.&#xD;
&#xD;
      LBH is a histone deacetylase (HDAC) inhibitor available also for oral administration.&#xD;
&#xD;
      In combination with platinum agents LBH589 could improve efficacy on DNA by multiple&#xD;
      non-exclusive mechanisms (by increasing drug access to chromosomal DNA, interfering with DNA&#xD;
      repair, modulating the levels of pro antiapoptotic genes or proliferation/survival genes).&#xD;
&#xD;
      The inclusion of Paclitaxel in the combination of LBH589 and Carboplatin is supported by the&#xD;
      results already available with the combination of the HDAC inhibitor Vorinostat&#xD;
      (suberoylanilide hydroxamic acid) given orally with carboplatin (AUC 6 mg/ml.h) and&#xD;
      paclitaxel (200 mg/m2) in a Phase I study in patients with solid tumors. The regimen proved&#xD;
      to be feasible, well tolerated and was associated with promising antitumor activity in&#xD;
      patients with NSCLC.&#xD;
&#xD;
      The mechanism of action, and the preliminary preclinical data, suggest that the combination&#xD;
      of LBH589, Carboplatin and Paclitaxel could be feasible and worthy of clinical investigation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) Recommended Dose (RD)</measure>
    <time_frame>3 weeks after the first drug administration (1 Cycle)</time_frame>
    <description>Number of Dose-Limiting Tocixities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hints of antitumor activity</measure>
    <time_frame>from first drug administration until tumor progression (every 6 weeks)</time_frame>
    <description>objective tumor responses based on RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of HDAC</measure>
    <time_frame>Cycle 1 on day 1, 4, 8, 15 and Cycle 2 on day 1, 8.</time_frame>
    <description>acetylation of histones, H3, H4 and tubulin in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>4 weeks after last drug administration</time_frame>
    <description>AE types and frequency monitored by laboratory and instrumental assessments, and physical examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Panobinostat (LBH589), Carboplatin and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat (LBH589), Carboplatin and Paclitaxel</intervention_name>
    <description>Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).&#xD;
Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).&#xD;
Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).&#xD;
The treatment will be repeated every three weeks until disease progression.</description>
    <arm_group_label>Panobinostat (LBH589), Carboplatin and Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological/cytological diagnosis of solid tumors in which treatment with Carboplatin&#xD;
             and Paclitaxel is indicated, e.g. NSCLC, GY tumors, prostate cancer, unknown primary&#xD;
&#xD;
          2. Progressive disease (also in terms of tumor markers only, like CA 125 for ovary and&#xD;
             PSA for prostate).&#xD;
&#xD;
          3. Age 18-75 years&#xD;
&#xD;
          4. Prior chemotherapy of ≤ 1 line for advanced disease&#xD;
&#xD;
          5. ECOG Performance Status &lt; 2&#xD;
&#xD;
          6. Life expectancy of at least 3 months&#xD;
&#xD;
          7. The patient must be able to read, understand and provide written evidence of informed&#xD;
             consent&#xD;
&#xD;
          8. Female patients may not be pregnant or lactating and must be willing to practice&#xD;
             contraception. The effects of LBH589 on the developing human fetus are unknown. For&#xD;
             this reason, women of childbearing potential must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control or abstinence) prior to study entry and&#xD;
             for the duration of study participation.&#xD;
&#xD;
          9. Male patients that are not surgically sterile must be practicing a medically&#xD;
             acceptable contraceptive regimen while on study treatment&#xD;
&#xD;
         10. Adequate organ function as defined by the following:&#xD;
&#xD;
               -  ANC &gt; 1500/µL&#xD;
&#xD;
               -  Platelets ≥ 100,000/µL&#xD;
&#xD;
               -  Haemoglobin ≥ 10 g/dl&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 60 ml/min&#xD;
&#xD;
               -  Magnesium, potassium and phosphorus ≥ the lower limit of normal or correctable&#xD;
                  with supplements&#xD;
&#xD;
               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤&#xD;
                  2.5 x ULN or ≤ 5.0 x ULN if hepatic involvement is present&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤ 2.5 x ULN or ALP &gt; 2.5 x UNL with liver fraction ≤&#xD;
                  2.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other chemotherapy treatment &lt; 4 weeks prior to enrolment&#xD;
&#xD;
          2. Hypersensitivity or allergic reactions to platinum compounds or Carboplatin®;&#xD;
             hypersensitivity or allergic reactions to Paclitaxel&#xD;
&#xD;
          3. Radiotherapy involving &gt; 30% of the active bone marrow&#xD;
&#xD;
          4. Radiotherapy &lt; 4 weeks prior to enrolment&#xD;
&#xD;
          5. Pre-existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          6. Pre-existing CTCAE hearing loss or tinnitus ≥ grade 2&#xD;
&#xD;
          7. Symptomatic pleural effusion&#xD;
&#xD;
          8. Clinically significant third space fluid accumulation (e.g. ascites,..)&#xD;
&#xD;
          9. Symptomatic brain metastasis or meningeal tumors&#xD;
&#xD;
         10. Patients who have not recovered (&gt; grade 1) from the following toxicities of previous&#xD;
             regimens before enrolment: fatigue, mucositis, nausea/vomiting, diarrhea&#xD;
&#xD;
         11. Concurrent enrolment, or previous enrolment within 30 days prior to registration in&#xD;
             another investigational device or drug trial(s) or is receiving other investigational&#xD;
             agent(s)&#xD;
&#xD;
         12. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         13. History of bone marrow or major organ transplant&#xD;
&#xD;
         14. Prior high dose treatment with PBSC support&#xD;
&#xD;
         15. Impaired cardiac function, including any one of the followings:&#xD;
&#xD;
               -  Complete Left Bundle Branch Block or obligate use of a cardiac pacemaker or&#xD;
                  congenital long QT syndrome or history or presence of atrial or ventricular&#xD;
                  tachyarrhythmias or clinically significant resting bradycardia (&lt; 50 beats per&#xD;
                  minute) or QTcF &gt; 480 msec on screening ECG or Right Bundle Branch block + left&#xD;
                  anterior hemiblock (bifascicular block)&#xD;
&#xD;
               -  Angina pectoris or acute MI ≤ 3 months prior to starting study drug&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g. congestive heart failure,&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen)&#xD;
&#xD;
         16. Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral LBH589 (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, malabsorption syndrome, or small bowel resection)&#xD;
&#xD;
         17. Acute or chronic liver or renal disease&#xD;
&#xD;
         18. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled&#xD;
             diabetes, active or uncontrolled infection, chronic obstructive or chronic restrictive&#xD;
             pulmonary disease) that could cause unacceptable safety risks or compromise compliance&#xD;
             with the protocol&#xD;
&#xD;
         19. Concomitant use of CYP3A4/5 inhibitors or inducers where the treatment can not be&#xD;
             discontinued or switched to a different medication prior to starting study drug&#xD;
             (medications listed in Appendix 3). The medications listed in Appendix 3 have a&#xD;
             relative risk of prolonging the QT interval or inducing Torsades de Pointes, but do&#xD;
             not represent an exclusion criteria&#xD;
&#xD;
         20. Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF,&#xD;
             GMCSF) ≤ 2 weeks prior to starting study drug.&#xD;
&#xD;
         21. Treatment with therapeutic doses of sodium warfarin (Coumarin ). Low doses of Coumarin&#xD;
             (e.g., ≤ 2 mg/day) for line patency is allowable&#xD;
&#xD;
         22. Patients who have received biologic therapy (excluding antiangiogenics) or&#xD;
             immunotherapy ≤ 2 weeks prior to starting study treatment or who have not recovered&#xD;
             from side effects of such therapy&#xD;
&#xD;
         23. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
         24. Unable or unwilling to comply with all study procedures&#xD;
&#xD;
         25. Current history of alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huniversitätsspitals Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mèdecin Adjoint, ME - CePO, CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>September 12, 2011</last_update_submitted>
  <last_update_submitted_qc>September 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>Panobinostat</keyword>
  <keyword>histone deacetylase inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

